Deepika Kumar, MD
Assistant Professor of PathologyDownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Contact Info
Pathology
310 Cedar Street, PO Box 208023
New Haven, CT 06512
United States
About
Titles
Assistant Professor of Pathology
Biography
Deepika Kumar received her medical school degree and completed a pathology residency from University of Mumbai, India. Thereafter, she did her residency training in Anatomic and Clinical Pathology at Yale New Haven Hospital in 2020, where she also served as a Chief resident (2019-20). She subsequently completed fellowship trainings in Hematopathology (2021), followed by Renal and Genitourinary pathology (2022), both at Yale. She is board-certified in Anatomic and Clinical Pathology and Hematopathology.
Appointments
Education & Training
- Clinical Fellow
- Yale-New Haven Hospital (2022)
- Clinical Fellow
- Yale-New Haven Hospital (2021)
- Chief Resident
- Yale-New Haven Hospital (2020)
- Residency
- Yale-New Haven Hospital (2019) (2019)
- MD
- University of Mumbai, Pathology (AP/CP) (2007)
- Residency
- L.T.M.M.C (University of Mumbai)
Board Certifications
Hematology (Pathology)
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2021
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2020
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Deepika Kumar's published research.
Publications Timeline
A big-picture view of Deepika Kumar's research output by year.
Mina Xu, MD
Dhanpat Jain, MD
Xuchen Zhang, MD, PhD
5Publications
68Citations
Publications
Featured Publications
Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis?
Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Human Pathology 2021, 113: 39-46. PMID: 33905775, DOI: 10.1016/j.humpath.2021.04.008.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMetastatic hepatocellular carcinomaHepatocellular carcinomaHistologic patternHistomorphologic featuresPrimary tumorMetastatic tumorsMacrotrabecular-massive hepatocellular carcinomaCommon histologic patternPathogenesis of metastasisSignificant intratumoral heterogeneityExtrahepatic metastasesLymph nodesMicrovascular invasionAdrenal glandCommon subtypeNoncirrhotic liverCirrhotic liverCommon siteMetastatic tissuesLarge cohortAbdominal cavityHCC subtypesPathology archivesMetastasisHCC metastasisMicroenvironment Cell Contribution to Lymphoma Immunity
Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLymphoma-associated macrophagesMesenchymal stem/stromal cellsT cellsLymphoma microenvironmentStromal cellsMarkers of exhaustionImmune checkpoint blockadeRegulatory T cellsEra of immunotherapyNatural killer cellsAnti-tumor effectsStem/stromal cellsLymphoma immunityTim-3Adverse eventsCheckpoint blockadeDendritic cellsImmune dysfunctionKiller cellsPD-1Immune cellsMechanisms of resistanceImmune escapeTumor surveillanceLAG-3Clinicopathological Review of Micropapillary Urothelial Carcinoma
Kumar D, Adeniran AJ. Clinicopathological Review of Micropapillary Urothelial Carcinoma. Current Oncology Reports 2022, 24: 603-610. PMID: 35199295, DOI: 10.1007/s11912-022-01219-x.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMicropapillary urothelial carcinomaUrothelial carcinomaNew therapeutic strategiesModerate interobserver reproducibilityClinicopathological reviewUrothelial componentAggressive variantHistopathologic characteristicsClinical managementWorse outcomesERBB2 amplificationTherapeutic strategiesDiagnostic criteriaReviewThis reviewCarcinomaOptimal managementReproducible criteriaInterobserver reproducibilityGenetic findingsIntratumoral heterogeneityHigh rateMolecular featuresRecent reportsLacunar spacesReviewBenign lymph node microenvironment is associated with response to immunotherapy
Toki MI, Kumar D, Ahmed FS, Rimm DL, Xu ML. Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Medicine 2020, 3: 44-53. PMID: 35693430, PMCID: PMC8985791, DOI: 10.1093/pcmedi/pbaa003.Peer-Reviewed Original ResearchCitationsAltmetricConceptsBenign lymph nodesLymph nodesT cellsQuantitative immunofluorescenceBenign lymphPD-L1Immune checkpoint blockade therapyMultiplexed quantitative immunofluorescenceHigh expressionCheckpoint blockade therapyMacrophage marker expressionSignificant differencesCytotoxic markersBlockade therapyBenign findingsCancer patientsLymphoid tissueImmune surveillanceTreatment responsePostmortem examinationImmunotherapyProliferation indexSplenic tissueB cellsPatients
2018
Corrigendum: Microenvironment Cell Contribution to Lymphoma Immunity
Kumar D, Xu ML. Corrigendum: Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 522. PMID: 30460201, PMCID: PMC6237016, DOI: 10.3389/fonc.2018.00522.Peer-Reviewed Original ResearchAltmetric
News
News
- August 15, 2023
Yale Pathology Validates Immunohistochemistry for Quick Assessment of NPM1-Mutated Acute Myeloid Leukemia
- June 14, 2022
Pathology and Laboratory Medicine Residents, Fellows Honored at Graduation Ceremony
- April 12, 2022
Yale Pathology Meets in Madison for Department Retreat; First In-Person Gathering Since Pandemic Began
- March 18, 2022
Yale Pathologists Participating in Annual USCAP Meeting to Share Research, Advancements
Get In Touch
Contacts
Mailing Address
Pathology
310 Cedar Street, PO Box 208023
New Haven, CT 06512
United States
Administrative Support
Locations
Brady Memorial Laboratory
Academic Office
310 Cedar Street
New Haven, CT 06510